Scientists are making waves with a novel therapy for metastatic colorectal cancer (mCRC) that combines two powerful antibodies–one targeting epidermal growth factor receptor (EGFR), the other programmed cell death 1 (PD-1). This dual treatment aims to supercharge the immune system, showing early signs of improving survival and response rates. For patients with no other treatment options, this breakthrough offers a glimmer of hope, potentially changing the trajectory of their fight against cancer.
Your privacy is our priority
- Hosted on Secure cloud-based hosting
- SOC II Type 1
- HIPAA compliant
- 2FA authentication
- End-to-end data encryption
- Your health data will not be sold or used without your consent. Ever.
